KONINKLIJKE PHILIPS NV (PHI1.DE) Fundamental Analysis & Valuation

FRA:PHI1 • NL0000009538

Current stock price

23.84 EUR
-0.16 (-0.67%)
Last:

This PHI1.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. PHI1.DE Profitability Analysis

1.1 Basic Checks

  • PHI1 had positive earnings in the past year.
  • PHI1 had a positive operating cash flow in the past year.
  • In multiple years PHI1 reported negative net income over the last 5 years.
  • Of the past 5 years PHI1 4 years had a positive operating cash flow.
PHI1.DE Yearly Net Income VS EBIT VS OCF VS FCFPHI1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2B 4B

1.2 Ratios

  • PHI1 has a Return On Assets (3.32%) which is comparable to the rest of the industry.
  • With a Return On Equity value of 8.17%, PHI1 perfoms like the industry average, outperforming 58.73% of the companies in the same industry.
  • PHI1 has a Return On Invested Capital (5.16%) which is comparable to the rest of the industry.
  • The Average Return On Invested Capital over the past 3 years for PHI1 is significantly below the industry average of 10.21%.
  • The last Return On Invested Capital (5.16%) for PHI1 is above the 3 year average (3.27%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 3.32%
ROE 8.17%
ROIC 5.16%
ROA(3y)-0.23%
ROA(5y)0.96%
ROE(3y)-0.52%
ROE(5y)1.86%
ROIC(3y)3.27%
ROIC(5y)N/A
PHI1.DE Yearly ROA, ROE, ROICPHI1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 20

1.3 Margins

  • Looking at the Profit Margin, with a value of 5.02%, PHI1 is in line with its industry, outperforming 46.03% of the companies in the same industry.
  • In the last couple of years the Profit Margin of PHI1 has declined.
  • With a Operating Margin value of 7.98%, PHI1 perfoms like the industry average, outperforming 44.44% of the companies in the same industry.
  • PHI1's Operating Margin has declined in the last couple of years.
  • PHI1 has a worse Gross Margin (45.18%) than 74.60% of its industry peers.
  • PHI1's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 7.98%
PM (TTM) 5.02%
GM 45.18%
OM growth 3YN/A
OM growth 5Y-5.27%
PM growth 3YN/A
PM growth 5Y-6.05%
GM growth 3Y3.66%
GM growth 5Y-0.43%
PHI1.DE Yearly Profit, Operating, Gross MarginsPHI1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20 30 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. PHI1.DE Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so PHI1 is destroying value.
  • The number of shares outstanding for PHI1 has been increased compared to 1 year ago.
  • PHI1 has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for PHI1 is higher compared to a year ago.
PHI1.DE Yearly Shares OutstandingPHI1.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M
PHI1.DE Yearly Total Debt VS Total AssetsPHI1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B

2.2 Solvency

  • An Altman-Z score of 1.99 indicates that PHI1 is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • PHI1 has a worse Altman-Z score (1.99) than 60.32% of its industry peers.
  • PHI1 has a debt to FCF ratio of 16.37. This is a negative value and a sign of low solvency as PHI1 would need 16.37 years to pay back of all of its debts.
  • With a Debt to FCF ratio value of 16.37, PHI1 perfoms like the industry average, outperforming 41.27% of the companies in the same industry.
  • PHI1 has a Debt/Equity ratio of 0.63. This is a neutral value indicating PHI1 is somewhat dependend on debt financing.
  • PHI1 has a worse Debt to Equity ratio (0.63) than 68.25% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.63
Debt/FCF 16.37
Altman-Z 1.99
ROIC/WACC0.84
WACC6.17%
PHI1.DE Yearly LT Debt VS Equity VS FCFPHI1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B 10B

2.3 Liquidity

  • PHI1 has a Current Ratio of 1.32. This is a normal value and indicates that PHI1 is financially healthy and should not expect problems in meeting its short term obligations.
  • PHI1 has a worse Current ratio (1.32) than 61.90% of its industry peers.
  • A Quick Ratio of 0.94 indicates that PHI1 may have some problems paying its short term obligations.
  • PHI1's Quick ratio of 0.94 is on the low side compared to the rest of the industry. PHI1 is outperformed by 61.90% of its industry peers.
Industry RankSector Rank
Current Ratio 1.32
Quick Ratio 0.94
PHI1.DE Yearly Current Assets VS Current LiabilitesPHI1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. PHI1.DE Growth Analysis

3.1 Past

  • The Earnings Per Share has been growing slightly by 6.11% over the past year.
  • The Earnings Per Share has been decreasing by -6.62% on average over the past years.
  • PHI1 shows a decrease in Revenue. In the last year, the revenue decreased by -1.03%.
  • PHI1 shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 0.59% yearly.
EPS 1Y (TTM)6.11%
EPS 3Y15.66%
EPS 5Y-6.62%
EPS Q2Q%-1.96%
Revenue 1Y (TTM)-1.03%
Revenue growth 3Y0.01%
Revenue growth 5Y0.59%
Sales Q2Q%1.05%

3.2 Future

  • The Earnings Per Share is expected to grow by 10.24% on average over the next years. This is quite good.
  • Based on estimates for the next years, PHI1 will show a small growth in Revenue. The Revenue will grow by 3.78% on average per year.
EPS Next Y4.04%
EPS Next 2Y8.35%
EPS Next 3Y10.36%
EPS Next 5Y10.24%
Revenue Next Year1.3%
Revenue Next 2Y2.87%
Revenue Next 3Y3.49%
Revenue Next 5Y3.78%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
PHI1.DE Yearly Revenue VS EstimatesPHI1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 5B 10B 15B 20B 25B
PHI1.DE Yearly EPS VS EstimatesPHI1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0.5 1 1.5 2

More info and screens

Find the best growth stocksShow best growing peers

4

4. PHI1.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 16.22, which indicates a correct valuation of PHI1.
  • Based on the Price/Earnings ratio, PHI1 is valued cheaply inside the industry as 88.89% of the companies are valued more expensively.
  • PHI1's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.91.
  • Based on the Price/Forward Earnings ratio of 15.59, the valuation of PHI1 can be described as correct.
  • Based on the Price/Forward Earnings ratio, PHI1 is valued a bit cheaper than the industry average as 66.67% of the companies are valued more expensively.
  • When comparing the Price/Forward Earnings ratio of PHI1 to the average of the S&P500 Index (23.68), we can say PHI1 is valued slightly cheaper.
Industry RankSector Rank
PE 16.22
Fwd PE 15.59
PHI1.DE Price Earnings VS Forward Price EarningsPHI1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • 74.60% of the companies in the same industry are more expensive than PHI1, based on the Enterprise Value to EBITDA ratio.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of PHI1 is on the same level as its industry peers.
Industry RankSector Rank
P/FCF 46.47
EV/EBITDA 11.08
PHI1.DE Per share dataPHI1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates PHI1 does not grow enough to justify the current Price/Earnings ratio.
PEG (NY)4.02
PEG (5Y)N/A
EPS Next 2Y8.35%
EPS Next 3Y10.36%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PHI1.DE Dividend Analysis

5.1 Amount

  • No dividends for PHI1!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PHI1.DE Fundamentals: All Metrics, Ratios and Statistics

KONINKLIJKE PHILIPS NV

FRA:PHI1 (4/9/2026, 7:00:00 PM)

23.84

-0.16 (-0.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-10
Earnings (Next)05-06
Inst Owners47.46%
Inst Owner ChangeN/A
Ins Owners0.06%
Ins Owner ChangeN/A
Market Cap22.96B
Revenue(TTM)17.84B
Net Income(TTM)895.00M
Analysts74.67
Price Target29.29 (22.86%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.35
Dividend Growth(5Y)216.55%
DP36.65%
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.02%
Min EPS beat(2)3.95%
Max EPS beat(2)14.1%
EPS beat(4)4
Avg EPS beat(4)17.83%
Min EPS beat(4)3.95%
Max EPS beat(4)31.04%
EPS beat(8)4
Avg EPS beat(8)2.84%
EPS beat(12)6
Avg EPS beat(12)6.47%
EPS beat(16)7
Avg EPS beat(16)6.93%
Revenue beat(2)0
Avg Revenue beat(2)-1.63%
Min Revenue beat(2)-2.4%
Max Revenue beat(2)-0.86%
Revenue beat(4)0
Avg Revenue beat(4)-1.8%
Min Revenue beat(4)-2.4%
Max Revenue beat(4)-0.86%
Revenue beat(8)0
Avg Revenue beat(8)-2.61%
Revenue beat(12)1
Avg Revenue beat(12)-2.36%
Revenue beat(16)2
Avg Revenue beat(16)-1.72%
PT rev (1m)0%
PT rev (3m)5.8%
EPS NQ rev (1m)-0.95%
EPS NQ rev (3m)-33.29%
EPS NY rev (1m)0%
EPS NY rev (3m)0.18%
Revenue NQ rev (1m)-0.13%
Revenue NQ rev (3m)5.94%
Revenue NY rev (1m)0.01%
Revenue NY rev (3m)-1.39%
Valuation
Industry RankSector Rank
PE 16.22
Fwd PE 15.59
P/S 1.29
P/FCF 46.47
P/OCF 19.76
P/B 2.09
P/tB N/A
EV/EBITDA 11.08
EPS(TTM)1.47
EY6.17%
EPS(NY)1.53
Fwd EY6.42%
FCF(TTM)0.51
FCFY2.15%
OCF(TTM)1.21
OCFY5.06%
SpS18.52
BVpS11.38
TBVpS-0.92
PEG (NY)4.02
PEG (5Y)N/A
Graham Number19.4
Profitability
Industry RankSector Rank
ROA 3.32%
ROE 8.17%
ROCE 7.33%
ROIC 5.16%
ROICexc 6.02%
ROICexgc 20.88%
OM 7.98%
PM (TTM) 5.02%
GM 45.18%
FCFM 2.77%
ROA(3y)-0.23%
ROA(5y)0.96%
ROE(3y)-0.52%
ROE(5y)1.86%
ROIC(3y)3.27%
ROIC(5y)N/A
ROICexc(3y)3.74%
ROICexc(5y)N/A
ROICexgc(3y)12.88%
ROICexgc(5y)N/A
ROCE(3y)4.66%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-1.19%
ROICexc growth 3YN/A
ROICexc growth 5Y-4.56%
OM growth 3YN/A
OM growth 5Y-5.27%
PM growth 3YN/A
PM growth 5Y-6.05%
GM growth 3Y3.66%
GM growth 5Y-0.43%
F-Score7
Asset Turnover0.66
Health
Industry RankSector Rank
Debt/Equity 0.63
Debt/FCF 16.37
Debt/EBITDA 2.72
Cap/Depr 59.38%
Cap/Sales 3.75%
Interest Coverage 5.63
Cash Conversion 45.59%
Profit Quality 55.2%
Current Ratio 1.32
Quick Ratio 0.94
Altman-Z 1.99
F-Score7
WACC6.17%
ROIC/WACC0.84
Cap/Depr(3y)53.03%
Cap/Depr(5y)53.41%
Cap/Sales(3y)3.68%
Cap/Sales(5y)4%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6.11%
EPS 3Y15.66%
EPS 5Y-6.62%
EPS Q2Q%-1.96%
EPS Next Y4.04%
EPS Next 2Y8.35%
EPS Next 3Y10.36%
EPS Next 5Y10.24%
Revenue 1Y (TTM)-1.03%
Revenue growth 3Y0.01%
Revenue growth 5Y0.59%
Sales Q2Q%1.05%
Revenue Next Year1.3%
Revenue Next 2Y2.87%
Revenue Next 3Y3.49%
Revenue Next 5Y3.78%
EBIT growth 1Y15922.2%
EBIT growth 3YN/A
EBIT growth 5Y-4.71%
EBIT Next Year68.67%
EBIT Next 3Y26.47%
EBIT Next 5Y17.86%
FCF growth 1Y-43.86%
FCF growth 3YN/A
FCF growth 5Y-22.31%
OCF growth 1Y-25.32%
OCF growth 3YN/A
OCF growth 5Y-15.14%

KONINKLIJKE PHILIPS NV / PHI1.DE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of KONINKLIJKE PHILIPS NV (PHI1.DE) stock?

ChartMill assigns a fundamental rating of 3 / 10 to PHI1.DE.


What is the valuation status for PHI1 stock?

ChartMill assigns a valuation rating of 4 / 10 to KONINKLIJKE PHILIPS NV (PHI1.DE). This can be considered as Fairly Valued.


What is the profitability of PHI1 stock?

KONINKLIJKE PHILIPS NV (PHI1.DE) has a profitability rating of 3 / 10.


What is the financial health of KONINKLIJKE PHILIPS NV (PHI1.DE) stock?

The financial health rating of KONINKLIJKE PHILIPS NV (PHI1.DE) is 2 / 10.


Can you provide the expected EPS growth for PHI1 stock?

The Earnings per Share (EPS) of KONINKLIJKE PHILIPS NV (PHI1.DE) is expected to grow by 4.04% in the next year.